IFNG and melanoma: First, we found that anti-IFN-γ treatment attenuated the antitumor activity of eBMDMs+HS treatment (Fig. 7b–d), and IFN-γ level decreased in the melanoma tissues after anti-IFN-γ treatment, as compared with control group treated with isotype control antibody (Fig. 7e).